Trial Profile
MK: Raltegravir Concentrations in Cerebrospinal Fluid
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 08 Aug 2019 Status changed from recruiting to completed.
- 11 Aug 2008 New trial record.